The FDA assessed the protection and success of atidarsagene autotemcel depending on information from 37 young children who been given atidarsagene autotemcel in two one-arm, open up-label scientific trials As well as in an expanded entry method.[seven] Small children who obtained treatment method with atidarsagene autotemcel ended up when compared